Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Osocimab in ESRD Patients on Hemodialysis
CTR20202567Phase 2Terminated
- Sponsor
- ---
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of osocimab in end-stage kidney disease (ESKD), thromboembolism, sponsored by ---. Started Jan 2021; status: terminated.
02
Drugs
osocimab
03
Conditions
end-stage kidney disease (ESKD)thromboembolism
Beyond the preview
Go deeper on CTR20202567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202567.